Loading...
Loading...
- Earlier today, SAB Biotherapeutics Inc's SABS SAB-176, an investigational therapy for post-exposure prophylaxis for influenza, received FDA Breakthrough Therapy Designation soon after securing FDA Fast Track Status for the candidate.
- Last Friday, SAB Biotherapeutics' 2022 10-K was released. The analyst says it has no impact on the company; unfortunately, this does not warrant any further investor focus.
- Also Read: EXCLUSIVE: SAB Biotherapeutics Says Influenza, COVID-19 Candidates Showing Broad Efficacy Against Variants.
- 4Q22 EPS was ($0.19), compared to HC Wainwright's estimate of ($0.04).
- The analyst says that the FDA is aligned with the company's manufacturing approach, which could address multiple strains of influenza annually.
- In December 2021, the company announced that SAB-176 met the primary endpoint of statistically significant reductions in viral load compared to the placebo.
- SAB expects SAB-176 to be treated like a vaccine with annual changes to its targets and readily available for each flu season.
- It forecasts a 2027 launch for SAB-176 with sales of $12.5 million that year and $290 million in 2030.
- HC Wainwright reiterates its Buy rating with a price target of $4.
- Chardan writes that SAB-176 is most likely to proceed with a partner. The analyst reiterates a Buy rating with a price target of $3.
- The analyst notes that SAB-195 is the company's top priority preclinical pipeline candidate for two infection indications.
- Preclinical data indicate that SAB-195 can neutralize both C. diff. bacteria and multiple strains of toxins. The company is conducting IND-enabling activities, with IND filing expected in 1Q24
- Price Action: SABS shares are up 40.30% at $1.08 on the last check Tuesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CareReiterationAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in